(redirected from antiviral resistance)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia.
Related to antiviral resistance: Resistance to antiviral drugs


An effective upper bound on prices achieved because of many willing sellers at that price level.

Resistance Level

In technical analysis, a price that a security does not, or only rarely, rise above. Technical analysts identify a resistance level by looking at past performance. When the security approaches the resistance level, it is seen as an indication to sell the security, which will increase the supply, causing the security's price to fall back below the resistance level. If there are too many buyers, however, the security rises above the resistance level. When this occurs, the price of the security will likely continue to rise until it finds another resistance level. It is also called the overhead resistance level. See also: Price ceiling, Support (Support level).


An increased supply of a security. Compare support.


Resistance, or resistance level, is the top of a stock's current trading range, and the point at which the price is higher than investors are willing to pay. As stockholders sell at resistance level, the stock price goes down because supply exceeds demand.

For example, if, on a repeated basis, as stock A's price reaches $60, stockholders begin to sell, then $60 is considered its resistance level. But a trading range isn't fixed and investor attitudes change, so the resistance level tends to move higher or lower over time.

If stock A rises to $63 without a surge of selling, the current resistance line has been breached. This may be the result of a rising market or a bullish assessment of the stock's value. On the other hand, if selling increases at $57, that may become the new resistance level.

Conversely, the level at which demand exceeds supply and investors typically buy a certain stock is called support. It's the point that's considered the bottom of a stock's current trading range.

Technical analysts use the concepts of resistance and support in anticipating future stock price movements.

References in periodicals archive ?
1] Additional members of the US Antiviral Resistance Surveillance Working Group who contributed data are listed at the end of this article.
Most patients infected with oseltamivir-resistant pandemic (H1N1) 2009 viruses were hospitalized (81%), had a severe immunocompromising condition (76%), and had been exposed to oseltamivir before collection of the specimen tested for antiviral resistance (89%) (Table); 9 (30%) had received oseltamivir as chemoprophylaxis, and 21 (70%) had received oseltamivir as treatment.
His research interests are vaccine development, antiviral resistance, and immunologic properties of influenza viruses.
Although the recently detected oseltamivir-resistant pandemic (H1N1) 2009 virus in Hong Kong was not a reassortant virus (4,5), we will continue to closely monitor antiviral drug resistance among circulating viruses, including pandemic (H1N1) 2009 virus and seasonal influenza virus A (H1N1), as well as influenza A (H3N2) viruses, to track how antiviral resistance evolves.
Based on the latest CDC influenza activity data, the influenza A (H1N1) virus appears to be the most prevalent strain circulating this flu season in the United States, but concern of antiviral resistance persists with the influenza A (H1N1) strain.
Antiviral resistance updates are available weekly at www.
The 2009 Influenza A H1N1 Antiviral Resistance test is designed to detect mutations of the pandemic Influenza strain that are resistant to oseltamivir (Tamiflu[R]).
Indiscriminant administration of these agents could support proliferation of antiviral resistance in pandemic (H1N1) 2009 virus or an evolved variant.
Antiviral resistance is a potentially significant issue when considering widespread use during the peak months of influenza season.